Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03881137
Other study ID # SI0303150406
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date May 8, 2019
Est. completion date June 10, 2022

Study information

Verified date November 2022
Source Sykehuset Innlandet HF
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

This cluster randomized controlled pilot study is designed to test the feasibility, and potential effect of a multicomponent, community-based intervention aiming to improve quality of life (QoL) and function for older patients receiving radiotherapy (RT), and thereby reduce the needs for professional help. The intervention will be based on geriatric assessment and management (GAM), i.e. systematic assessment and management of physical, mental and functional problems frequently occurring in the elderly. It will target individual patients according to needs and be carried out in collaboration between hospital and community services from start of RT until 8 weeks post-treatment.


Description:

Background: Older cancer patients (> 65 years) represent the majority of the cancer population, and their number grows due to an aging population. These patients often present with a multiplicity of problems. They frequently suffer from physical- or mental health comorbidities, and are often frail with impairment in mobility, daily life functioning and cognition. When diagnosed with cancer and in need of therapy, they are at substantial risk of complications and functional decline. Geriatric assessment with management (GAM) has documented success in improving outcomes in older patients with other diseases than cancer. Thus, GAM is strongly recommended as an approach to optimize treatment and care for older cancer patients. Evidence for the potential benefits is still scarce and in particular for older patients receiving radiotherapy. Although GAM has been proven successful in other contexts, there is no universally accepted recipe for how such an intervention should be performed and implemented. To be feasible and efficient, adjustments according to patient population, health care organization and available resources are necessary. The present study will be conducted to provide the evidence needed for a subsequent definitive evaluation of a GAM intervention for older patients receiving radiotherapy in a larger RTC, aiming at improving quality of life (QoL) and function, and thereby reduce the burden for the patients, their families and the society. The detailed objectives are to: 1. assess the potential short- and long-term effect of the intervention on global QoL and physical functioning for older cancer patients receiving RT 2. assess the feasibility of the intervention 1. at the patient level (recruitment, compliance and adherence) 2. at the organizational level (structures facilitating or impeding implementation and collaboration across sectors and between professionals) 3. study the use of health care services and related costs in the intervention and control group Methods: The study emerges from Innlandet Hospital Trust and will be conducted in cooperation with Trondheim University Hospital, and 30 municipalities in the catchment area of Innlandet Hospital Trust, and Trondheim Municipality. The intervention is developed by an interdisciplinary, experienced research group in close collaboration with user representatives, hospital- and primary health care professionals. It is based on experience, results and preliminary results from foregoing studies by our study group (including NCT03071640 and NCT01742442) and focus group interviews with health professionals. The design is cluster-randomized, randomizing municipalities and city districts. Patients will be recruited at the radiotherapy units at Innlandet Hospital Trust (primary study center) and Trondheim University Hospital (second study center). Anticipated number of participants from the two hospitals is 102 patients and 60 patients, respectively. Eligible, consenting patients will be included by the start of radiotherapy (RT), and enter the control or intervention groups in accordance with the assignment of the municipality or city district in which they reside. They will be followed with study specific assessments for one year after end of RT, and for survival for five years. Assessments: By the time of inclusion, demographic and medical characteristics (including cancer diagnosis, stage of disease, former and ongoing tumor treatment, ECOG performance status, RT treatment aim (palliative or curative), and comorbidity. Detailed information about the RT schedule will be registered by the end of RT. Patient reported outcomes (EORTC QLQ-C30 and EQ-5D-5L) will be assessed at baseline, by the end of RT, and thereafter 4, 8, 16, 32 and 52 weeks after RT. Physical performance tests, i.e. Short Physical Performance Battery (SPPB), Timed Up and Go (TUG), grip strength and one-legged balance test, will be applied at baseline and 8 and 16 weeks after the end of RT. Cognitive function will be tested at baseline using the MiniCog. To evaluate the cost-effectiveness of the intervention in comparison to control (standard care), detailed information on the patients' use of health care services (home based and institutional care) will be registered throughout the intervention period and during follow-up (one year, week 52). Feasibility will be assessed by a process evaluation, aiming to identify facilitators and barriers for a successful implementation, using mixed methodology. Measures recommended for each patient's intervention plan will be consecutively registered, as will patients' compliance and adherence through weekly contact with the coordinating nurse (log notes). Further data will include interviews with patients and providers. Questionnaires to involved primary health care nurses and other relevant professionals will also be applied.


Recruitment information / eligibility

Status Completed
Enrollment 178
Est. completion date June 10, 2022
Est. primary completion date July 25, 2021
Accepts healthy volunteers No
Gender All
Age group 65 Years and older
Eligibility Inclusion Criteria: - =65 years of age - confirmed cancer diagnosis (histology/cytology) - living in one of the participating municipalities in the catchment area of Innlandet Hospital Trust or in the municipality of Trondheim - referred for palliative or curative RT - fluency in Norwegian, orally and in writing - ability to fill in self-report questionnaires - provide written informed consent Exclusion Criteria: - severely ill with a life expectancy < 3months - referred to receive one fraction of RT only (one day treatment)

Study Design


Related Conditions & MeSH terms


Intervention

Other:
Geriatric assessment with management
A multicomponent intervention, carried out in cooperation between hospital and community services, based on a geriatric assessment (GA) followed by individually adapted measures targeting identified needs. The GA and the start of the intervention will be handled by a PhD student (geriatrician) or project cancer nurse at start of RT. Pre-planned guidelines will be followed. Contribution from relevant hospital professionals will be sought according to needs. Then the intervention will be offered in the primary health care taking advantage of existing services, e.g. home care, rehabilitation services, exercise groups etc. A community-based coordinating nurse will follow the patients with weekly contacts throughout RT and to end of intervention 8 weeks post-RT. To ensure that each patient's intervention is properly adjusted to changing needs, repeated clinical assessments will be performed by the end of RT and 4 weeks post-RT.

Locations

Country Name City State
Norway Innlandet Hospital Trust Gjøvik
Norway St Olav Hospital, Trondheim University Hospital Trondheim

Sponsors (7)

Lead Sponsor Collaborator
Sykehuset Innlandet HF Norwegian University of Science and Technology, Oslo Metropolitan University, Oslo University Hospital, Trondheim Kommune, Trondheim University Hospital, University of Oslo

Country where clinical trial is conducted

Norway, 

References & Publications (1)

Røyset I, Saltvedt I, Rostoft S, Grønberg BH, Kirkevold Ø, Oldervoll L, Bye A, Benth JŠ, Bergh S, Melby L, Halsteinli V, Døhl Ø, Røstad T, Eriksen GF, Sollid MIV, Rolfson D, Slaaen M. Geriatric assessment with management for older patients with cancer receiving radiotherapy. Protocol of a Norwegian cluster-randomised controlled pilot study. J Geriatr Oncol. 2022 Apr;13(3):363-373. doi: 10.1016/j.jgo.2021.11.001. Epub 2021 Nov 12. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Other mobility assessed by the Timed Up and Go 8 weeks after radiotherapy and trend during follow-up up to 16 weeks after radiotherapy)
Other balance registration of the time the patient is able to maintain balance on one leg 8 weeks after radiotherapy and trend during follow-up up from inclusion to 16 weeks after radiotherapy
Other symptom occurence measured by the EORTC QLQ-C30 questionnaire 8 weeks after radiotherapy and trend during follow-up from inclusion to one year after radiotherapy
Other Body mass index (BMI) Body mass inndex assessed as weight (kg)/(height m2) From baseline throughout follow-up up to 52 weeks after RT
Other appetite loss (AL) Assessed by the appetite loss subscale on the EORTC QLQ-C30 questionnaire. The scale ranges from 0 (best) to 100 (worse). To be noted is that for all symptom scales of the EORTC QLQ -C30, 0 indicates the best (no symptom), whereas 100 is the worse. This is opposite to the functioning scales such as physical function, global QoL and emotional function 8 weeks after radiotherapy and trend during follow-up from inclusion to one year after radiotherapy
Other emotional functioning (EF) assessed by the emotional function subscale of theEORTC QLQ-C30 questionnaire. The scale ranges from 0 (worse) to 100 (best) 8 weeks after radiotherapy and trend during follow-up from inclusion to one year after radiotherapy
Primary physical function physical function as assessed by patient report using the EORTC QLQ-C30 questionnaire. The analysis will assess the difference between control and intervention groups in physical function measured by the EORTC QLQ-C30 questionnaire at 8 weeks after baseline. Longitudinal analysis of covariance will be performed by estimating a linear mixed model with fixed effects for baseline values, time and interaction between time and group variable. The model will include random effects for patients nested within study cluster. 8 weeks following termination of radiotherapy (RT)
Secondary physical function physical function as assessed by patient report using the physical function scale from the EORTC QLQ-C30. The scale ranges from 0 (worse) to 100 (best) trend during follow-up from inclusion to one year after termination of radiotherapy
Secondary global health assessed by the EORTC QLQ-C30 questionnaire's global health/quality of life (QoL) sub-scale (question 29 and 30). The scale ranges from 0 (worse) to 100 (best) 8 weeks after radiotherapy and trend during follow-up from inclusion to one year after radiotherapy
Secondary Health related quality of life (HRQoL) assessed by the EQ-5D-5L index values 8 weeks after radiotherapy and trend during follow-up from inclusion to one year after radiotherapy
Secondary mobility assessed by the short physical performance battery (SPPB) 8 weeks after radiotherapy and trend during follow-up from inclusion up to 16 weeks after radiotherapy
Secondary grip strength assessed by dynamometer 8 weeks after radiotherapy and trend during follow-up from inclusion up to 16 weeks after radiotherapy
Secondary the incremental cost-effectiveness ratio (ICER) We will calculate the intervention cost based on a micro-costing approach. Cost-effectiveness of the intervention will be evaluated by calculating the incremental cost-effectiveness ratio (ICER) that is the difference in mean costs divided by the difference in mean Quality Adjusted Life Years (QALYs). We calculate QALYs by an area under the curve approach under the assumption of piecewise linear change in EQ-5D-5L-index values over time. Missing data will be imputed by multiple imputation and the uncertainty of the ICER will be assessed by performing sensitivity analysis including application of bootstrapping techniques. 8 weeks after radiotherapy and during follow-up (up to 52 weeks after after radiotherapy)
Secondary Use of health care services use of health care services (hospital in- and outpatient services and municipality services in terms of home care, nursing home care and use of other services such as general practitioner, physiotherapist, occupational therapists, and rehabilitation programs) From inclusion through overall follow-up (up to 52 weeks after radiotherapy)
See also
  Status Clinical Trial Phase
Recruiting NCT05346796 - Survivorship Plan HEalth REcord (SPHERE) Implementation Trial N/A
Recruiting NCT05094804 - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents Phase 1/Phase 2
Completed NCT04867850 - Effect of Behavioral Nudges on Serious Illness Conversation Documentation N/A
Enrolling by invitation NCT04086251 - Remote Electronic Patient Monitoring in Oncology Patients N/A
Completed NCT01285037 - A Study of LY2801653 in Advanced Cancer Phase 1
Completed NCT00680992 - Study of Denosumab in Subjects With Giant Cell Tumor of Bone Phase 2
Completed NCT00062842 - Study of Irinotecan on a Weekly Schedule in Children Phase 1
Active, not recruiting NCT04548063 - Consent Forms in Cancer Research: Examining the Effect of Length on Readability N/A
Completed NCT04337203 - Shared Healthcare Actions and Reflections Electronic Systems in Survivorship N/A
Recruiting NCT04349293 - Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways N/A
Terminated NCT02866851 - Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy N/A
Active, not recruiting NCT05304988 - Development and Validation of the EFT for Adolescents With Cancer
Completed NCT04448041 - CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
Completed NCT00340522 - Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
Recruiting NCT04843891 - Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis. Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Completed NCT03167372 - Pilot Comparison of N-of-1 Trials of Light Therapy N/A
Completed NCT03109041 - Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source Phase 1
Terminated NCT01441115 - ECI301 and Radiation for Advanced or Metastatic Cancer Phase 1
Recruiting NCT06206785 - Resting Energy Expenditure in Palliative Cancer Patients